Kornimate/medical-research-clean huggingface dataset:
multimodal imaging evaluation and prognostic analysis of participants after arterial switch operation

Conditions: Arterial Switch Operation

Summary: the aims of this study are to 1. identify the early and midterm outcomes in terms of mortality and reoperation of the arterial switch operation (aso). 2. identifying the influence of coronary artery anomalies on the in-hospital and post-discharge prognosis after aso. 3. evaluate the predictors for neoaortic valve regurgitation after aso. 4. explore the risk factors for neopulmonary artery stenosis after aso.

this study will enroll participants with transposition of the great arteries (tga) and double outlet right ventricle with subpulmonary ventricular septal defect (vsd) (taussig-bing anomaly, tba). the cardiac structure and function will be evaluated by multimodal imaging including transthoracic echocardiographic examination, stress echocardiography, cardiac computed tomography scan, cardiovascular magnetic resonance imaging. and the study aimed to: 1. identify the early and midterm outcomes in terms of mortality and reoperation of the arterial switch operation (aso) in participants with transposition of the great arteries (tga) and double outlet right ventricle with subpulmonary ventricular septal defect (vsd) (taussig-bing anomaly, tba). 2. identifying subclinical coronary abnormalities and silent myocardial ischemia by multimodel imaging, further determine the influence of coronary artery anomalies on the in-hospital and post-discharge prognosis in participants with tga and tba after aso. 3. evaluate the time course and predictors for neoaortic root dilatation and neoaortic valve regurgitation in participants with tga and tba after aso by multimodel imaging. 4. assess the structure of the right ventricular outflow tract and neopulmonary artery in participants with tga and tba after aso by multimodel imaging, and explore the incidence and risk factors for neopulmonary artery stenosis.

Eligibility criteria:
inclusion criteria: ·participants with the diagnosis of tga or tba underwent aso. exclusion criteria: * patients with various forms of tga undergoing réparation à l'etage ventriculaire procedure * patients with various forms of tga undergoing rastelli procedure * patients with various forms of tga undergoing nikaidoh procedure * patients with various forms of tga undergoing fontan operation * patients with various forms of tga undergoing atrial repair (mustard or senning) operations * aso is used as a corrective therapy for prior operations.
detection of reductions in cystic fibrosis airway inflammation while using aztreonam lysine solution

Conditions: Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa

Summary: in cystic fibrosis, there is a critical need for better predictors of treatment response. the investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with cystic fibrosis. these biomarkers predict reduction of airway inflammation and infection more accurately than lung function testing, in patients receiving intravenous antibiotic therapy. in the current study, we hypothesize that this panel of gene biomarkers which can be readily measured from peripheral blood will sensitively predict changes in inflammation when patients receive inhaled antibiotic therapy, specifically cayston (or inhaled aztreonam lysine). patients enrolled in the study will have blood drawn before and after a month of inhaled cayston, in order to test whether genes predict response to cayston therapy more robustly than do standard measures such as lung function tests.


Eligibility criteria:
inclusion criteria: * documented diagnosis of cystic fibrosis * age 18 years old or greater * fev1 percent predicted greater than 25% * ability to perform reproducible pulmonary function tests and produce sputum spontaneously * chronic bacterial colonization with pseudomonas aeruginosa with 2 positive cultures in previous 2 years. * chronically stable pulmonary condition without evidence of acute pulmonary exacerbation within 14 days prior to screening * starting cayston cycle as part of clinical care. exclusion criteria: * presence of a condition or abnormality that, in the opinion of the principal investigator (pi), would compromise the safety of the patient or the quality of the data. * aztreonam allergy, bronchospasm or other contraindication to use of aztreonam. * signs and symptoms of acute pulmonary exacerbation at the time of enrollment or during study. * active infection and treatment for non-tuberculous mycobacteria. * concomitant use of systemic steroids. * use of inhaled antimicrobial agents with activity against pseudomonas aeruginosa within 28 days prior to visit 1.
appetite regulation and mycoprotein

Conditions: Appetite; Energy Intake

Summary: the purpose of this study is to investigate the effect of eating various levels of mycoprotein (quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing t2dm

Eligibility criteria:
inclusion criteria: * males and females between the ages of 18 and 65 * body mass index (bmi) 25-32kg/m2 * weight stable over the past 6 months * no known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels. * no paracetamol or other analgesic in the previous 48 hours * a score of \<2.5 in the dutch eating behaviour questionnaire (debq) * a score of \<2 in the scoff questionnaire exclusion criteria: * persons outside the age and bmi ranges stated above * pregnant and lactating women * weight variation of greater than 5% in the last 6 months * any diagnosed major illness * any paracetamol or analgesic intake in the last 48 hours * diagnosed eating disorder * allergy to mycoprotein or mushrooms * regular consumption of quorn products * dislike of any of the test foods or drinks * a score of \>2.5 in the dutch eating behaviour questionnaire * a score of 2 or more in the scoff questionaire

Keywords: appetite overweight energy intake obesity gut hormones
calcinosis in a single-center scleroderma population

Conditions: Scleroderma; Calcinosis

Summary: this is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2) to identify common complications associated with scleroderma-related calcinosis. .

this is a prospective study of scleroderma- spectrum patients focused on soft tissue calcinosis in order 1) to better understand the risk factors (including clinical/laboratory characteristics, and serology) of calcinosis in the scleroderma-spectrum disorders (limited or diffuse systemic sclerosis with or without overlap of inflammatory arthritis and/or myositis). 2) view common complications associated with calcinosis. better understanding of scleroderma calcinosis would lead to other studies that eventually will define better treatment options for this incurable and often disabling complication.

Eligibility criteria:
inclusion criteria: * adult scleroderma subjects with and without calcinosis exclusion criteria: * subjects unwilling to participate

Keywords: scleroderma calcinosis
effect study of parecoxib to treat emergence delirium and postoperative pain

Conditions: Emergence Delirium; Postoperative Pain

Summary: this prospective, double blind, placebo-controlled, parallel group study will be conducted in three study centers in guangzhou, china. patients aged older than 65 (asa i-iii) undergoing primary elective abdominal surgery with general anesthesia will be involved in this study. according to previous studies and our pilot trial, the sample size was estimated to be 900 subjects (each center recruiting 300 patients). all eligible patients will be randomly assigned to one of two groups: study group receiving parecoxib and control group receiving normal saline. all patients will be managed with by a standard clinical anesthesia protocol with a sevoflurane-based general anesthesia with continuous intravenous remifentanil, followed by a postoperative pca with morphine. the emergence delirium will be evaluated by two persons blinding to medication and grouping using riker sedation-agitation scale immediately since tracheal extubation and at specific time points until patients being discharged from pacu. pain intensity assessments and pain relief assessments will also be conducted by the patients at given time points in 2 days postoperatively. the morphine-sparing effect, tolerability and safety of parecoxib will be investigated as well.

the inclusion criteria of this study includes: * aged older than 65; * primary elective abdominal surgery under general anesthesia; * ability to understand how to use pain assessment scales and pca device. the outcome measures of this study includes: * emergence delirium assessment; * pain intensity and pain relief efficacy endpoints; * tolerability and safety assessments

Eligibility criteria:
inclusion criteria: * aged older than 65; * body weight of at least 50 kg; * primary elective abdominal surgery under general anesthesia; * preoperative health graded as class asa i-iii, based on medical history and physical examination; * ability to understand how to use pain assessment scales and pca device exclusion criteria: * emergency or revised abdominal surgery; * history of known use of analgesics or any other agent that could interfere with analgesic responses during the up to 24 h before receipt of the study medication which including nsaids, tricyclic antidepressants, neuroleptic or antipsychotic agents, or corticosteroids (except routine preoperative medication); * history of known or suspected drug abuse; * known allergy, sensitivity, or contraindication to opioid and non-opioid analgesic drugs; * history of bleeding disorders, peptic ulceration, or anticoagulant use within the past month; * history of asthma or bronchospasm; * history of inflammatory bowel disease, a chronic or acute renal or hepatic disorder, coronary heart disease; * history of dementia and psychological disorder; * contraindication to parecoxib.

Keywords: parecoxib; emergence delirium; postoperative pain; elderly patients; abdominal surgery parecoxib on emergence agitation and postoperative pain
effectiveness of a community - based cross-sector network for the management of mental health problems and disorders associated with forced displacement due to armed conflict in the municipality of soacha - cundinamarca

Conditions: Mental Disorder; Mental Disorder in Adolescence; Mental Problems; Mental Disorder in Infancy

Summary: it is of great importance to generate interventions that help ensure greater inclusion and social participation of the population that was and is a victim of the armed conflict, especially in the post-conflict transition in colombia, and to influence development in the post-accord period through relationships between groups and society. therefore, the question for this investigation is, what is the effectiveness of a community-based cross-sector network for the management of mental problems and disorders associated with forced displacement due to armed conflict in the commune of soacha - cundinamarca, in order to contribute to inclusion and social participation in the post-accord period? objective: to design a community-based cross-sector network for the management of mental problems and disorders associated with forced displacement due to armed conflict in the commune of soacha - cundinamarca, in order to contribute to inclusion and social participation in the post-accord period in colombia.


Eligibility criteria:
inclusion criteria: • children (7 to 11 years old), adolescents (12 to 18 years old) and adults (\>18 years old) who have been victims of the armed conflict in the municipalities of soacha - cundinamarca, occurring during the last 5 years prior to the start of the project exclusion criteria: • people with neurocognitive disorders
signaling pathway activation after exercise in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (copd). although resistance exercises increase strength and muscle mass in patients with copd, the response to training appears to be suboptimal in these individuals. a dysregulation in the signaling pathways involved in the regulation of muscle mass could play an important role in this phenomenon. hypothesis: proteins involved in muscle mass regulation will be less activated in the quadriceps of patients with copd following the acute bout of resistance training exercise compared to healthy age-matched controls.

our objective is to investigate the impact of an acute bout of resistance training on key signaling pathways involved in the regulation of muscle mass in moderate to severe copd (fev1 under 60% of predicted). key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured before after 72 contractions of the quadriceps. the exercise protocol was designed to match the actual exercise prescription model use in the context of pulmonary rehabilitation. a squat, leg press and leg extension will be done at 80% of max with one minute rest between sets. a biopsy of the quadriceps will be done before and after exercise in order to measure phosphorylated kinases, total protein content and mrna expressions. all our patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition.

Eligibility criteria:
inclusion criteria: * male * copd with an fev1 of under 60% of predicted * non-smoker * between 50 and 75 years old exclusion criteria: * all inflammatory disease (hiv, cancer, renal and cardiac deficiency) * hormonal dysregulation * inferior limb pathology * neuromuscular pathology * history of tabacco or alcool abuse * oxygen dependent * recent exacerbation (2 months) of the symptoms of copd

Keywords: copd exercise training
a study to evaluate virologic response in participants newly diagnosed with hiv-1

Conditions: HIV

Summary: the purpose of this study is to determine the proportion of newly diagnosed participants with human immunodeficiency virus (hiv)-1 (naive participants) with virologic response at week 48-defined as hiv-1 ribonucleic acid (rna) less than (\<) 50 copies/milliliter (ml) (food and drug administration snapshot) - after the implementation of the test \& treat model of care and in a historical cohort.


Eligibility criteria:
inclusion criteria: * prospective cohort: newly diagnosed with human immunodeficiency virus (hiv)-1 evidenced by any of the following: or hiv rapid antibody positive; hiv immunoassay positive; positive hiv (p24) antigen; or detectable hiv-1 ribonucleic acid (rna) viral load and non-reactive antibody/antigen assays. hiv-1 rna viral load must be confirmed within one week of initial hiv-1 rna viral load test * prospective cohort: antiretroviral (arv) treatment-naïve who will initiate treatment. retrospective cohort: dates of hiv-1 diagnosis and arv treatment initiation available in clinical records * prospective and retrospective cohorts: must sign \[and/or their legally-acceptable representative where applicable must sign,\] a participation agreement/ informed consent form (icf) allowing data collection and source data verification in accordance with local requirements exclusion criteria: * known acquired immune deficiency syndrome (aids)-defining condition * known history of clinically relevant hepatic disease or hepatitis that in the investigator's judgement is not compatible with antiretroviral therapy (art) * known history of chronic renal insufficiency, defined as having an egfr less than (\<) 50 milliliter/minute (ml/min) according to the cockcroft-gault formula * known active severe infections (other than hiv-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to screening * known history of cirrhosis as diagnosed based on local practices
suspicion of hypoglycemic effect of mrna based covid-19 vaccines (polyethylene glycol) will happen , observational study on diabetic patients at saudia arabia

Conditions: Diabetic Complication; Covid19 Virus Infection; Hypoglycemia; Polyethylene Glycol Adverse Reaction

Summary: vaccines for covid-19 are gold strategy and great achievement at this century for protection against complications of covid-19 , development of many vaccines with different technology represent a big challenge for this disease so the world live bad days and the vaccines save world to see the light once again , mrna based vaccines have a new technology which designed before for cancer therapy, this technology is very effective , producible and fast for future disease targets but these vaccine must contain excipients for preservation of this technology mrna so we now study these side effects of excipients and we suspect that polyethylene glycol as excipients have big role at hypoglycemic effects with antidiabetic medications like metformin and insulin especially at children and older age

diabetics patients as chronic diseases represent high percentage at all the world and high priority for vaccines against covid-19 so we will focus on these group as need more attention and need best health and quality of life so my study concentrate on diabetics patients from 12 years to 80 years who were taken mrna based vaccines and suffer from recurrent hypoglycemia , i will check the blood glucose one month after the first or second injection of mrna based vaccines pfizer or moderna vaccines and study all medicines taken by patients and suspect what's happen is there is hypoglycemic effect or nor by following up the readings of blood glucose by glucometers or cgm there are previous studies about relation of metformin and polyethylene glycol injection and this study conclude that the subcutaneous injection of pex168 once a week can effectively, continuously and safely improve hba1c levels in patients with t2d when combined with metformin ( gao f, lv x, mo z, ma j, zhang q, yang g, liu w, li q, zhou j, bao y, jia w. efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 3b trial. diabetes obes metab. 2020 dec;22(12):2375-2383. doi: 10.1111/dom.14163. epub 2020 sep 6. pmid: 32744358.

Eligibility criteria:
inclusion criteria: - male and female subjects between the ages of 12 and 80 years, inclusive, with type 1 or 2 diabetes mellitus as defined by the american diabetes association (diabetes care, vol. 21: s5- s19, 1998) for more than one year. exclusion criteria: * under 12 years above 80 years undergone bariatric surgery no exercises during testing
reference curve on bone mineral density in young adult: french multicenter study

Conditions: Bone Mineral Density; Grip Strength; Physical Performance

Summary: in men, the hope of lower life, the absence of equivalent of menopause and the existence of a higher peak bone mass are three factors that explain the lower incidence of osteoporosis in men. epidemiological data indicate a prevalence of 15% among men aged over 50 years (szulc et al. 2000). according to global analyzes, the number of fractures of the upper end of the femur in humans will increase from 400 000 to 800 000 per year between 2000 and 2025 (kanis et al. 2004). furthermore the mortality due to major osteoporotic fractures when they occur in humans than that seen in women (johnell and al.2001).the main goal of this study is to establish reference curves in elderly male volunteers from 20 to 30 years through the assessment of bone mineral density of the spine, hip, and the measurement of body composition (fat mass, lean mass). this study will allow us to establish the mean and standard deviation of the value of the young adults of the same sex, which will eventually be applied in the calculation of the "t-score" for older people.


Eligibility criteria:
inclusion criteria: * male * aged between 20 and 30 years * caucasians exclusion criteria: * lack of informed consent * pieces of metal or plastic parts in the field * diseases which cause technical difficulties for the correct evaluation of the hip and spine (severe dysplasia, hip surgery or lumbar spine)
impact of chest wall mechanics on lung and cardiovascular function during delayed sternal closure

Conditions: Palliation of Congenital Heart Diseases; Cardiopulmonary Bypass; Chest Wall Mechanics; Neonatal Delayed Sternal Closure

Summary: this study aims to describe chest wall mechanics during delayed sternal closure (dsc) in neonates following cardiopulmonary bypass or palliation of congenital heart diseases.

this research study is being done so that investigators can understand the complex interactions between the heart, the lungs and the chest wall after heart surgery. understanding this may guide future care that can help patients with their recovery from heart surgery. the heart and lungs work together to make sure the body has the oxygen-rich blood it needs to function properly. the chest wall protects the heart, lungs, and other important organs. investigators would like to learn how a patient's chest wall contributes to the heart and lungs interaction when the chest is left open after heart surgery. investigators will be using a device called an esophageal pressure catheter to estimate the pressure that is transmitted to the lungs and heart, called pleural pressure. previous research has shown that this pressure measurement is used to adjust the breathing machine for patients with lung diseases. measuring the pressure transmitted to the lungs and heart after heart surgery and delayed chest wall closure may help investigators understand how the chest wall contributes to the heart and lung interaction.

Eligibility criteria:
inclusion criteria: 1. informed consent provided by parent or primary guardian. 2. aged \<28 days of life at the time of cardiac surgery. 3. undergone surgery using cpb for congenital heart disease. 4. undergoing dsc in cccu. exclusion criteria: 1. gestational age \< 37 weeks or weight \< 2 kg at the time of surgery. 2. endotracheal tube leak \>20%. 3. need of extracorporeal support (ecmo), inhaled nitric oxide. 4. pre-existing pulmonary disease (for example: congenital diaphragmatic hernia). 5. pre-existing or new arrhythmia that can impact hemodynamic assessment. 6. severe coagulopathy or any other contraindication for the insertion of a nasogastric catheter (e.g., history of tracheo-esophageal fistula).

Keywords: chest wall mechanics congenital heart disease neonates delayed sternal closure cardiopulmonary bypass